Log In
Print this Print this

follow-on insulin glargine biologic, Lusduna, biosimilar insulin glargine (MK-1293, SB9)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFollow-on biologic of Lantus insulin glargine, a synthetic sustained-release subcutaneous insulin analog
Molecular Target Insulin receptor (INSR)
Mechanism of ActionInsulin receptor agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentRegistration
Standard IndicationDiabetes
Indication DetailsTreat diabetes in patients aged two and older; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation
PartnerBiogen Inc.;
Samsung Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today